ABC | Volume 115, Nº2, Agosto 2020

Artigo Original Jardim et al. Tratamento multidisciplinar da hipertensão Arq Bras Cardiol. 2020; 115(2):174-181 Este é um artigo de acesso aberto distribuído sob os termos da licença de atribuição pelo Creative Commons 19. Malachias MVB, Amodeo C, Paula RB, Cordeiro Jr AC, Magalhães LBNC, Bodanese LC. 7th Brazilian Guideline of Arterial Hypertension: Chapter 8 - hypertension and associated clinical conditions. Arq. Bras. Cardiol. 2016;107(3 supl 3):44-8. 20. LopesRD,BarrosoWKS,BrandaoAA,BarbosaECD,MalachiasMVB,Gomes MM, et al. The First Brazilian Registry of Hypertension. Am Heart J. 2018 Nov;205:154-7. 21. PinhoNA, Pierin AMG. Hypertension control in brazilian publications. Arq. Bras. Cardiol. 2013;101(3):e65-e73. 22. Jardim TV, Reiger S, Abrahams-Gessel S, Gomez-Olive FX, Wagner RG, Wade A, et al. Hypertensionmanagement in a population of older adults in rural South Africa. J Hypertens. 2017;35(6):1283-9. 23. Folb N, Timmerman V, Levitt NS, Steyn K, Bachmann MO, Lund C, et al. Multimorbidity, control and treatment of noncommunicable diseases among primary healthcare attenders in the Western Cape, South Africa. S Afr Med J. 2015;105(8):642-7. 24. GillespieCD, Hurvitz KA, Centers for DiseaseControl and Prevention (CDC). Prevalence of hypertension and controlled hypertension - United States, 2007-2010. MMWR Suppl. 2013;62(3):144-8. 25. Grossman A, Grossman E. Blood pressure control in type 2 diabetic patients. Cardiovasc Diabetol. 2017;16(1):3. 26. Krieger EM, Drager LF, Giorgi DMA, Pereira AC, Barreto-Filho JAS, Nogueira AR, et al. Spironolactone versus clonidine as a fourth-drug therapy for resistant hypertension: the ReHOT randomized study (Resistant Hypertension Optimal Treatment). Hypertension. 2018;71(4):681-90. 27. Wang H, Zhang X, Zhang J, He Q, Hu R, Wang L, et al. Factors associated with prevalence, awareness, treatment and control of hypertension among adults in southern China: a community-based, cross-sectional survey. PLoS One. 2013;8(5):e62469. 28. Tipton AJ, Sullivan JC. Sex differences in blood pressure control: are T lymphocytes the missing link? Hypertension. 2014;64(2):237-9. 29. Harbour R, Miller J. A new system for grading recommendations in evidence based guidelines. BMJ. 2001;323(7308):334-6. 30. Stanley K. Design of randomized controlled trials. Circulation. 2007;115(9):1164-9. 31. Nallamothu BK, Hayward RA, Bates ER. Beyond the randomized clinical trial: the role of effectiveness studies in evaluating cardiovascular therapies. Circulation. 2008;118(12):1294-303. 32. Jacob V, Chattopadhyay SK, Thota AB, Proia KK, Njie G, Hopkins DP, et al. Economics of team-based care in controlling blood pressure: a Community Guide Systematic Review. Am J Prev Med. 2015;49(5):772-83. 33. Sousa AC, Jardim TV, Costa TO, Magalhães FG, Montelo MPM, Souza WKB, et al. Hypertensive diabetic patients: incidence of cardiovascular and renal outcomes in a historical cohort over 11 years. Diabetol Metab Syndr. 2017;9:98. 34. BarrosoWKS, JardimPCB, JardimTSV, Souza CTS, Magalhães ALA, Ibrahim FM, et al. Hypertensive diabetic patients: guidelines for conduct and their difficulties. Arq Bras Cardiol. 2003;81(2):143-7. 181